Che-Wei Hsu

About Che-Wei Hsu

Che-Wei Hsu is an Independent Director of ABVC BioPharma and a current Board nominee; she was also nominated in the 2024 proxy cycle. She is 43, holds a B.A. in Chinese Literature from Tunghai University (2004), and works as a clerk at Chunghwa Post Co., Ltd. since August 2016; previously she was a junior high school teacher .

Past Roles

External Roles

• No other public-company directorships disclosed .
• Current employment: Clerk, Chunghwa Post Co., Ltd. (non-board role) .

Board Governance

• Committee assignments and chair roles:
  • Audit Committee: Member; Chair is Yen-Hsin Chou. Chou is designated the Audit Committee financial expert; Hsu is independent per Nasdaq standards .
  • Compensation Committee: Member; Chair is Norimi Sakamoto. All members, including Hsu, deemed independent .
  • Corporate Governance & Nominating Committee: Member; Chair is Yoshinobu Odaira. All members, including Hsu, deemed independent .
• Independence: Board explicitly identifies Hsu as independent for Audit, Compensation, and Nominating committees .
• Attendance: Not disclosed.
• Board size and composition context: 11 directors; nine non-management; several family relationships on the Board (multiple Jiang family ties; marital relationship between Odaira and Sakamoto), which is a structural independence consideration .

Fixed Compensation

• Director cash retainers, chair/member fees, meeting fees: Not disclosed in the proxy filings.
• Equity grants to directors in FY2024: Company states no stock options were paid to directors in fiscal year 2024 .

Performance Compensation

• Individual director performance-metric-linked pay (e.g., PSUs, TSR metrics): Not disclosed for Hsu.
• Plan mechanics context: Company seeks stockholder approval to increase shares available under its Equity Incentive Plan and add an automatic annual increase (potential future equity usage affecting directors and executives) .

Other Directorships & Interlocks

• Other public-company boards: None disclosed for Hsu .
• Potential interlocks: None disclosed for Hsu; note broader Board family relationships (Jiang family; Odaira–Sakamoto) .

Expertise & Qualifications

• Education: B.A., Chinese Literature, Tunghai University (2004) .
• Professional background: Government postal operations (clerical) since 2016; prior teaching experience .
• Audit Committee financial expertise: Not designated; the committee’s financial expert is Yen-Hsin Chou .
• Governance skill signals: Service on all three key committees (Audit, Compensation, Nominating), indicating engagement across oversight domains .

Equity Ownership

• No pledging or hedging of company stock disclosed; no Form 4 trading detail provided in proxy .

Governance Assessment

• Strengths:
  • Independent director serving on Audit, Compensation, and Nominating committees; independence affirmed by the Board for these committees .
  • Meaningful increase in beneficial ownership from 336 shares (2023) to 41,489 shares (2025), signaling improved alignment with shareholders .
• Concerns and RED FLAGS:
  • Limited disclosed financial/biopharma expertise relative to Audit and Compensation oversight duties; audit committee’s “financial expert” is another member (Chou), not Hsu .
  • Board-level related-party exposure: a proposed land purchase from director Shuling Jiang paid in stock/warrants (requires shareholder approval due to Nasdaq rules), raising conflict-of-interest oversight demands on independent directors, including Hsu .
  • Structural independence risk: multiple family relationships among directors (Jiang family; Odaira–Sakamoto) may impair board independence dynamics, increasing reliance on truly independent directors like Hsu to assert robust governance .
  • Transparency gaps: no disclosure of director attendance rates, cash retainers, or committee fees; limited individual director compensation detail for Hsu (only that no director options were paid in FY2024) .
• Additional governance signals:
  • Company disclosed it had no compensation clawback recoveries required for the last fiscal year under Item 402(w), amid a restatement context, which should remain on investor radar for internal controls quality .